SCHEMBL21428758

SCHEMBL21428758

C=CC(=O)N1CCCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 15/20 0.95
EGFR P00533 8/20 0.95
BMX P51813 5/20 0.95
ITK Q08881 4/20 0.95
TEC P42680 3/20 0.95
HCK P08631 3/20 0.95
SRC P12931 3/20 0.95
BLK P51451 3/20 0.95
TXK P42681 2/20 0.95
LYN P07948 2/20 0.95
FGFR2 P21802 2/20 0.95
NUDT5 Q9UKK9 2/20 0.95
JAK3 P52333 2/20 0.95
RIPK2 O43353 1/20 0.95
NR1I2 O75469 1/20 0.95
SLC22A3 O75751 1/20 0.95
LATS1 O95835 1/20 0.95
NUDT14 O95848 1/20 0.95
ABL1 P00519 1/20 0.95
ERBB2 P04626 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ibrutinib SCHEMBL2244865 0.98 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201642 0.98 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL2244870 0.98 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201641 0.98 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL201859 0.98 BTK (1.00) BTKEGFRBMXITKTEC
SCHEMBL200392 0.94 BTK (1.00) BTKEGFRBMXITKTEC
SCHEMBL200391 0.94 BTK (1.00) BTKEGFRBMXITKTEC
SCHEMBL201548 0.94 BTK (1.00) BTKEGFRBMXITKTEC
Ibrutinib SCHEMBL16887867 0.92 BTK (0.93) BTKEGFRBMXITKTEC
SCHEMBL1613606 0.91 EGFR (0.90) BTKEGFRBMXITKTEC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019185117-A1 NEW COMPOUNDS WITH ENHANCED ANTI-TUMOR EFFECTS FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR) (CH) 2019-10-03 WO disclosed